XIGDUO XR is not indicated for glycemic control in patients with type 1 diabetes mellitus
2024 Mar;119(3):599-627 Alba Miguns-Gmez # 1, ngela Casanova-Mart # 1, M Teresa Blay 1, Ximena Terra 1, Ral Beltrn-Debn 1, Esther Rodrguez-Gallego 1, Anna Ardvol 1, Montserrat Pinent 1
Despite advancements in ultra-fast and ultra-long-acting insulins, there has been a paucity of new non-insulin glucose-lowering therapies specifically licensed for type 1 diabetes
While emerging research suggests gut bacteria may influence metabolic health, the evidence supporting probiotics for meaningful weight loss remains limited and preliminary
As a result, GL-1RAs play a role in reversing or improving VSMC dysfunction by suppressing VSMCs proliferation, migration, apoptosis, as well as inhibiting VSMC phenotypic switching, especially inhibiting osteoblastic differentiation
These FDA-approved treatments support appetite regulation, enhance fullness, slow digestion and aid metabolic health all important tools when lifestyle changes alone arent enough